Basilea's Toctino cleared by SMC
Switzerland-based firm Basilea Pharmaceutica's Toctino (alitretinoin), an oral capsule for the treatment of severe chronic hand eczema, has been approved for use on the National Health Service in Scotland. The news sent shares up 13.2% to 63.65 Swiss francs.
The Scottish Medicines Consortium provides advice to NHS Boards and associated committees in Scotland regarding financial support of all newly-licensed medicines.
Toctino is the only therapy approved in Scotland for severe CHE unresponsive to potent topical corticosteroids. The NHS list price for the drug in England and Wales is set at GBP411.73 ($726.29) per month, or 13.71 - 17.00 euros ($24.15) - per day (Marketletter September 15, 2008).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze